Application of anti-thymocyte immune globulin preparation in liver transplantation immune induction
By administering anti-thymocyte immunoglobulin intravenously during and after liver transplantation, the problem of high rejection rates after liver transplantation has been solved, leading to rapid recovery of liver function and lymphocyte levels, reducing the risk of acute rejection and infection, and expanding the scope of application.
Patent Information
- Application Number
- CN202511873882.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-12-12
- Publication Date
- 2026-01-23
AI Technical Summary
In current technologies, the incidence of rejection after liver transplantation is high, affecting graft function and recipient survival, and there is a lack of effective immunosuppressive induction therapy programs.
During and after liver transplantation, antithymocyte immunoglobulin preparations are administered intravenously, specifically 50 mg during surgery and 25 mg daily for 3 consecutive days after surgery, at a dose of 0.4-1.5 mg/kg, for a course of 3-7 days.
It significantly reduced the incidence of acute rejection, maintained normal liver function and lymphocyte levels, did not increase the risk of kidney damage or cytomegalovirus infection, and broadened its clinical application prospects.
Smart Images
Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
TECHNICAL FIELD
[0001] The application belongs to the technical field of biological medicine, and particularly relates to application of an anti-thymocyte immunoglobulin preparation in liver transplantation immune induction. BACKGROUND
[0002] Liver transplantation is an effective treatment for end-stage liver disease. Although the incidence and severity of rejection after liver transplantation are significantly lower than those of other solid organs, rejection is still a common complication after liver transplantation, with an incidence of 15% to 25%, which seriously affects the function of the graft and the survival of the recipient. Anti-thymocyte immunoglobulin is a polyclonal antibody gamma globulin that can recognize various cell surface proteins, remove T cells, reduce leukocyte adhesion and migration, interfere with dendritic cell function, and induce the production of tolerogenic dendritic cells and regulatory T cells. It is suitable for anti-rejection of solid organ transplantation such as liver transplantation and kidney transplantation, and can improve the survival rate of the graft and the recipient. Currently, interleukin-2 receptor blockers are commonly used for immune induction therapy during liver transplantation to delay the use of CNI and reduce its dosage, and to reduce the amount of hormone used. There is no treatment regimen for liver transplant recipients using anti-thymocyte immunoglobulin for immune induction. SUMMARY
[0003] To solve the problems mentioned in the background, the purpose of the present application is to provide an application of an anti-thymocyte immunoglobulin preparation in liver transplantation immune induction, which can rapidly restore liver function and lymphocyte levels to normal range, has no significant effect on kidney function, reduces the incidence of acute rejection, and does not increase the incidence of cytomegalovirus infection.
[0004] The purpose of the present application can be achieved by the following technical solutions: An application of an anti-thymocyte immunoglobulin preparation in liver transplantation immune induction, wherein the anti-thymocyte immunoglobulin preparation is intravenously dripped before the portal vein is opened during the operation, and is continuously intravenously dripped after the operation.
[0005] Preferably, the anti-thymocyte immunoglobulin preparation is administered at a dose of 50mg intravenously before the portal vein is opened during the operation, and is administered at a dose of 25mg intravenously every day for 3 consecutive days after the operation.
[0006] Preferably, the anti-thymocyte immunoglobulin preparation is administered at a single dose before the portal vein is opened during the operation, and is administered for 2 to 4 times, with a treatment course of 3 to 7 days after liver transplantation.
[0007] Preferably, the single dose is 0.4 to 1.5mg / kg.
[0008] The present application has the following advantages: The application utilizes the anti-thymocyte immunoglobulin preparation in the application of liver transplantation immune induction, has low risk of related adverse reactions, can rapidly restore the liver function and lymphocyte level of the liver transplantation recipient to the normal range, has no significant influence on the kidney function, reduces the incidence of acute rejection, and does not increase the cytomegalovirus infection rate. The application expands the clinical application of the anti-thymocyte immunoglobulin preparation in the immune induction of liver transplantation recipients, and has great application prospect. DETAILED DESCRIPTION
[0009] The technical solutions in the embodiments of the application will be clearly and completely described in combination with the embodiments of the application. Obviously, the described embodiments are only part of the embodiments of the application, rather than all the embodiments of the application. Based on the embodiments in the application, all other embodiments obtained by those skilled in the art without creative labor fall within the protection scope of the application.
[0010] Clinical case verification: A, the general conditions of the liver transplantation recipients are shown in Table 1. Table 1 General conditions of liver transplantation recipients
[0011] As shown in Table 1, the application of the anti-thymocyte immunoglobulin preparation in the liver transplantation immune induction has a wide application population.
[0012] B, the intraoperative and postoperative indexes of the liver transplantation recipients are shown in Table 2. Table 2 Intraoperative and postoperative index results of liver transplantation recipients
[0013] As shown in Table 2, the application of the anti-thymocyte immunoglobulin preparation in the liver transplantation is safe.
[0014] C, the postoperative liver function, kidney function and blood routine indexes of the liver transplantation recipients are shown in Table 3. Table 3 Postoperative liver function, kidney function and blood routine index results of liver transplantation recipients
[0015] As shown in Table 3, the application of the anti-thymocyte immunoglobulin preparation in the liver transplantation can rapidly restore the liver function and lymphocyte level of the liver transplantation recipient to the normal range, and has no significant influence on the kidney function.
[0016] D, the postoperative infection indexes of the liver transplantation recipients are shown in Table 4. Table 4 Postoperative infection index results of liver transplantation recipients
[0017] As shown in Table 4, the application of anti-thymocyte immunoglobulin preparation does not increase the incidence of postoperative infection after liver transplantation.
[0018] In the description of the present specification, the description of the terms "one embodiment", "an example", "a specific example" and the like means that the specific features, structures, materials or characteristics described in connection with the embodiment or example are included in at least one embodiment or example of the present application. In the present specification, the illustrative expressions of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner.
[0019] The basic principles, main features and advantages of the present application are shown and described above. It should be understood by those skilled in the art that the present application is not limited by the above embodiments, and the above embodiments and descriptions in the specification are only illustrative of the principles of the present application. Without departing from the spirit and scope of the present application, various changes and improvements can be made to the present application, and these changes and improvements all fall within the scope of the claimed present application.
Claims
1. The application of an anti-thymocyte immunoglobulin preparation in liver transplantation immune induction, characterized in that, The anti-thymocyte immunoglobulin preparation was administered intravenously before the portal vein was opened during surgery, and continued intravenously after surgery.
2. The application of the anti-thymocyte immunoglobulin preparation according to claim 1 in liver transplantation immune induction, characterized in that, The method of administration for the anti-thymocyte immunoglobulin preparation is to administer 50 mg intravenously before the portal vein is opened during surgery, and 25 mg intravenously daily for 3 consecutive days after surgery.
3. The application of the anti-thymocyte immunoglobulin preparation according to claim 1 in liver transplantation immune induction, characterized in that, The anti-thymocyte immunoglobulin preparation is administered as a single injection before the portal vein is opened during surgery, with a total of 2-4 injections. The course of treatment ends 3-7 days after liver transplantation.
4. The application of the anti-thymocyte immunoglobulin preparation according to claim 3 in liver transplantation immune induction, characterized in that, The single dose is 0.4~1.5 mg / kg.